Dr. Saree Alnaghy is an Honorary Associate Professor at the University of Wollongong's Faculty of Engineering and Information Sciences, affiliated with the Centre for Medical Radiation Physics. She holds a Bachelor of Medical and Radiation Physics (Honours) and a PhD in Physics from the University of Wollongong (2009–2017). Her research focuses on advanced medical imaging and radiation therapy technologies, including photon counting detectors, dosimetry systems, and robotic motion phantoms for quality assurance. Key research areas include: Development of novel X-ray detectors for radiotherapy guidance High-resolution dosimetry techniques using silicon and polymer-based systems Integration of real-time imaging in radiation therapy Robotic systems for motion management in oncology Her work has been supported by grants such as 'Sharper Targeting, Brighter Future' (2024) and 'Bringing Colour to Radiotherapy' (2021–2025). She currently supervises PhD and MRes students on projects involving photon counting CT scanners and radiotherapy imaging. Alnaghy also serves as a Radiation Oncology Medical Physics Registrar at the Nelune Comprehensive Cancer Centre.
Dr. Owen Dillon is a Research Fellow in the Discipline of Medical Imaging Sciences at the University of Sydney's Faculty of Medicine and Health. He holds affiliations with the ACRF Image X Institute and the Dodd-Walls Centre for Photonic and Quantum Technologies. His work focuses on advanced imaging techniques for medical applications, particularly computed tomography (CT) and motion compensation in radiation therapy. He completed his PhD in Mathematics at the University of Auckland, specializing in probabilistic compression algorithms for inverse problems. Education: B.Sc. Physics & Applied Mathematics (2013, University of Auckland), First Class Honours in Mathematics (2015), PhD Mathematics (2018). Research interests include inverse problems, Bayesian statistics, CT image reconstruction, and real-time imaging systems. Current projects involve optimizing CT acquisition geometries, motion-compensated 4D imaging, and anatomical motion estimation. His contributions have led to clinical trials reducing radiation dose and scan times. He advises two PhD students and collaborates on grants like the Quantum CT project. Grants: 'Quantum CT for Cancer Diagnosis' (2024), 'Functional Imaging in Lung Cancer' (2024). His work bridges mathematical theory with clinical applications in oncology and interventional radiology.
Professor Ananya Choudhury serves as Chair and Honorary Consultant in Clinical Oncology at the University of Manchester, where she is also Co-Group Leader of the Translational Radiobiology Group within the Division of Cancer Sciences. She joined The Christie NHS Foundation Trust in 2008, specializing in urology and sarcoma, and has since focused on radiotherapy-related research in prostate and bladder cancers. Professor Choudhury is clinical lead for advanced radiotherapy, including the groundbreaking MRLinac project, and plays a key role in national radiotherapy research initiatives. Professor Choudhury earned her BA (Hons) in 1993, MB. BChir (Cantab) in 1995, and MA (Cantab) in 1997 from Trinity College, Cambridge. She completed her Clinical Oncology training at the Yorkshire Deanery from 2000-2008, during which she earned her MRCP in 2000 and F.R.C.R in 2004. She completed her PhD in 2008 through the University of Leeds and Princess Margaret Hospital in Toronto, Canada, where she studied the molecular epidemiology of DNA double strand break repair in bladder cancer. Professor Choudhury's research program focuses on optimizing and personalizing radiotherapy using advanced imaging technology to deliver high doses while minimizing side effects. Her work centers on prostate and bladder cancers, with particular interest in predictive biomarkers, hypoxia, and the integration of magnetic resonance imaging to improve treatment precision. She has pioneered research in radiotherapy dose optimization, biomarker development, and the identification of patients who would benefit most from different treatment approaches. Her extensive publication record demonstrates a strong focus on radiation therapy, particularly in genitourinary cancers. Recent work explores MRI-guided radiotherapy, hypoxia biomarkers, and personalized treatment approaches across multiple cancer types. She has made significant contributions to understanding how imaging technology can improve radiotherapy precision and effectiveness while reducing side effects, with several publications appearing in top journals through 2025. Professor Choudhury has received multiple prestigious awards recognizing her contributions to the field: Cancer Research-UK/Royal College of Radiologists Clinical Training Fellowship (2005) Fellowship for the 10th ECCO-AACR-ASCO Workshop on Methods in Clinical Cancer Research (2007) Outstanding Contribution, Greater Manchester Clinical Research Awards (2017) RCR Research Fellowship (2005) Research Fellowship, Princess Margaret Hospital, Toronto (2004) Professor Choudhury has supervised numerous doctoral and master's students across multiple cancer types, with current students expected to complete through 2024. She is Principal Investigator on multiple research grants, including 'Measuring tumour radioresistance to improve radiotherapy outcomes' and the 'MAESTRO Programme' as part of CRUK RadNet. Her research program is supported by significant funding from NIHR Manchester Biomedical Research Centre and other major funding bodies. As Co-Group Leader of the Translational Radiobiology Group, Professor Choudhury collaborates extensively with leading researchers including Peter Hoskin, Catharine West, Corinne Faivre-Finn, and Marcel van Herk. Her team is at the forefront of integrating advanced imaging with radiotherapy to improve cancer treatment outcomes, with active projects spanning from basic radiobiology to clinical implementation of novel radiotherapy techniques.
Dan Nguyen, Ph.D., is a faculty member in the Department of Radiation Oncology at UT Southwestern Medical Center, where he is part of the Division of Medical Physics and Engineering. He is a founding member of the Medical Artificial Intelligence and Automation (MAIA) Laboratory, collaborating closely with Dr. Steve Jiang to advance AI applications in radiotherapy. His work focuses on deep learning for treatment planning, dose prediction, auto-segmentation, and adaptive radiotherapy. Ph.D. in Biomedical Physics, University of California, Los Angeles (UCLA), 2017 Mentor: Dr. Ke Sheng Faculty appointment at UT Southwestern since 2017 Dr. Nguyen’s research is centered on applying artificial intelligence to solve critical challenges in radiation oncology. His primary interests include deep learning-based dose prediction, auto-segmentation of anatomical structures, optimization of treatment plans, and real-time adaptive radiotherapy. He has pioneered work in direct aperture optimization, 4π radiotherapy, and uncertainty quantification in AI models. His research bridges the gap between AI innovation and clinical implementation, with a focus on improving plan quality, reducing planning time, and enhancing accessibility for less experienced clinicians. The most recent publications (2023–2025) demonstrate a consistent trend in developing fast, accurate, and robust deep learning models for radiotherapy. Key themes include dose prediction with transfer and meta-learning, adaptive segmentation using test-time optimization, uncertainty assessment in AI predictions, and mathematical modeling of radiotherapy-immunotherapy synergy. These works span high-impact journals in medical physics, AI, and oncology, reflecting interdisciplinary innovation. While no specific scientific awards are listed, Dr. Nguyen’s leadership in the MAIA Lab and extensive publication record in top-tier journals indicate significant recognition in the field of medical physics and AI in medicine. Dr. Nguyen has co-authored numerous studies involving mentoring and collaborative research, particularly with trainees and junior faculty in the MAIA Lab. His work is supported by institutional and likely federal funding, given the scale and scope of AI deployment studies. He has contributed to large-scale collaborative efforts such as OpenKBP-Opt, involving international teams evaluating knowledge-based planning pipelines. The MAIA Laboratory is a multi-investigator research group focused on innovating, developing, and applying artificial intelligence technologies to empower clinicians—especially those with less experience or limited resources—for improved patient care. The lab’s work spans machine learning, deep learning, reinforcement learning, and mathematical modeling in radiation oncology.
Dr Emily Hewson is a Cancer Institute NSW Early Career Fellow and member of the Sydney School of Health Sciences at the University of Sydney's Faculty of Medicine and Health. Her research focuses on advancing real-time radiation therapy techniques, particularly in managing intrafraction motion for prostate and other cancers. She leads projects involving multileaf collimator (MLC) tracking, dose optimization, and deep learning integration in radiation oncology. Research interests include adaptive radiotherapy systems, kilovoltage intrafraction monitoring (KIM), and clinical trial implementation (e.g., TROG 15.01 SPARK trial). Her work emphasizes improving treatment accuracy through real-time dose-guided approaches and multitarget tracking for tumors with complex motion patterns. Developed experimental validations for MRI-linac integration and MLC tracking systems Authored a textbook chapter on Adaptive Radiation Therapy (ART) Recipient of Cancer Institute NSW Early Career Fellowship (2023) Recent grants include an AI platform for targeted radiotherapy (2024) and national critical infrastructure funding for lung cancer applications (2023). Her lab collaborates on real-time dose calculation algorithms and clinical trial implementation across multiple institutions.
Dr. Chad J. Brenner is an Associate Professor in the Department of Otolaryngology-Head and Neck Surgery and Pharmacology at the University of Michigan Medical School. He also directs the U-M Program in Cellular and Molecular Biology, the Otolaryngology Clinical Laboratory (CLIA), and the Head & Neck Oncology Program. His research focuses on developing liquid biopsy tools for cancer detection and precision therapy, particularly in HPV-driven head and neck cancers. Key roles include membership in the Rogel Cancer Center, Kresge Hearing Research Institute, and Center for Computational Medicine & Bioinformatics. Education: B.S. in Biomedical Engineering, M.S. in Bioelectrical Engineering, and Ph.D. in Cellular and Molecular Biology from the University of Michigan, with doctoral work on prostate cancer mechanisms. Research Interests: HPV integration and cancer heterogeneity Urine- and blood-based liquid biopsies for real-time cancer monitoring Combination immunotherapy strategies for improving checkpoint inhibitor responses Genetic engineering to identify cancer vulnerabilities Clinical trial innovation for adaptive therapies Recent Work Highlights: Development of the MyHPVscore blood test for HPV-related head and neck cancer detection, and exploration of tumor-immune interactions through PD-L1 and T-cell profiling. Ongoing projects include PET-guided radiotherapy optimization and multi-omics analyses of tumor heterogeneity. Labs & Teams: Leads the Michigan Otolaryngology and Translational Oncology (MiOTO) lab and collaborates with interdisciplinary teams across computational medicine, immunology, and clinical oncology.
Huixiao Chen is an Assistant Professor and Clinical Medical Physicist II in the Department of Therapeutic Radiology at Yale School of Medicine. She holds a primary appointment in Therapeutic Radiology and is actively engaged in clinical and research activities related to radiation oncology physics. Assistant Professor, Department of Therapeutic Radiology, Yale School of Medicine Clinical Medical Physicist II, Therapeutic Radiology Education: Resident, Yale University (2016) Postdoctoral Fellow, Harvard University (2013) Postdoctoral Fellow, Virginia Commonwealth University (2011) PhD, University of Heidelberg, Germany (2010) MS, Zhejiang University, China (1998) BS, Zhejiang University, China (1995) Huixiao Chen's research centers on medical physics in radiation oncology, with a focus on treatment planning optimization, dosimetry, and image-guided radiotherapy. Her work includes the development and evaluation of advanced radiotherapy techniques such as VMAT and SBRT, with applications in spine, lung, and prostate cancers. She has contributed to improving the accuracy of dose calculations using Monte Carlo methods and has explored the impact of patient motion on treatment delivery. Her research also extends to the design of clinical devices to support safe and effective radiotherapy for diverse patient populations. Her recent publications demonstrate a consistent focus on enhancing the precision and efficiency of radiotherapy. Key themes include multicriteria optimization in treatment planning, dosimetric validation of radiochromic films, and the development of supportive devices for image-guided radiotherapy. These works reflect a strong commitment to advancing clinical medical physics through both computational and engineering innovations. Scientific Contributions: Characterization of GafchromicTM EBT4 film for clinical dosimetry Design of a small-footprint couch-top support for heavy patients in IGRT Application of multicriteria optimization in VMAT planning for spine and prostate cancers Comparison of Monte Carlo vs. pencil beam algorithms in lung SBRT Analysis of diaphragm motion effects on spine SBRT Huixiao Chen has collaborated with researchers such as Emily Draeger and Zhe Jay Chen on various projects. While no formal students or grants are listed, her role as a clinical medical physicist and faculty member suggests active mentorship and potential involvement in funded research. She is a key contributor to the medical physics team at Yale, ensuring high standards in treatment planning and delivery.
Dr Arran K Turnbull is a Senior Lecturer and Group Leader at the Edinburgh Cancer Research Centre, MRC Institute of Genetics and Cancer, University of Edinburgh, leading the Translational Oncology Research Group focused on breast and prostate cancer mechanisms and biomarker development. Education: BSc (Hons) in Molecular Biology, MSc(Res) in Immunology, Genetics and Pathway Medicine, MBChB from University of Glasgow, and PhD in Oncology from University of Edinburgh. Research Interests: Specializes in estrogen receptor positive and HER2-positive breast cancer, investigating endocrine therapy resistance through high-throughput multiomics approaches including RNA/DNA sequencing, proteomics, and spatial genomics. Key focus areas include treatment response prediction, DCIS biomarker discovery, and prostate cancer radiotherapy resistance mechanisms, translating findings into clinically applicable diagnostic tools. Scientific Awards: Breast Cancer Now Researcher of the Year award (2018) Sir Antony Driver Prize (2018) Advising and Grants: Supervises PhD students Charlene Kay (node-positive ER+ breast cancer risk prediction) and Zuzanna Gedziorowska (prostate cancer biomarker discovery). Current funding includes Breast Cancer Now, Breast Cancer Institute, The Urology Foundation, Royal Society of Edinburgh, Tenovus Scotland, CSO, NHS Lothian Charity, John Black Foundation, and NIH grants. Laboratory and Collaborations: Leads a multidisciplinary team including postdoctoral researchers, PhD students, research nurses, and bioinformaticians. Maintains active national/international partnerships with University of North Carolina, Georgetown University, University of Hong Kong, and industry collaborators including AstraZeneca and Philips.
Brian Kavanagh, MD, MPH is a Professor and Department Chair of Radiation Oncology at the University of Colorado Anschutz Medical Campus School of Medicine. He serves as Department Chair and maintains clinical practice at multiple UCHealth locations including the University of Colorado Cancer Center, Cherry Creek Medical Center, Longs Peak Medical Center, and the Rocky Mountain Gamma Knife Center. His leadership extends to serving as Chair of the American Society for Radiation Oncology since 2017. MD, Tulane University School of Medicine (1988) MPH, Tulane University (1988) BSE, Tulane University (LA) (1984) Internship: Tulane University Program (1989) Residency: Duke University Hospital Program, Radiation Oncology (1993) Dr. Kavanagh's research primarily focuses on stereotactic body radiation therapy (SBRT), functional lung avoidance radiation therapy using 4DCT-ventilation imaging, and treatment of brain metastases from oncogene-driven lung cancers. His work bridges clinical practice, medical physics innovation, and outcomes research, with particular emphasis on optimizing radiation therapy techniques while minimizing toxicity. Recent publications demonstrate his leadership in developing novel approaches to image-guided radiation therapy, including antiscatter grid technology for CBCT imaging and functional avoidance techniques for lung cancer treatment. Analysis of Dr. Kavanagh's recent publications (2019-2024) reveals a strong focus on precision radiation therapy for lung cancer and brain metastases. His research spans technical innovations in medical physics (such as 2D antiscatter grid development), clinical trials evaluating functional avoidance radiation therapy, and studies examining outcomes for patients with oncogene-driven cancers. A significant portion of his work addresses the integration of radiation therapy with targeted therapies for lung cancer with brain metastases, reflecting the evolving treatment paradigms in this field. Top Doctor, 5280 Magazine (2023) Dr. Kavanagh has been instrumental in developing national radiation oncology curriculum frameworks through stakeholder consensus processes. His leadership in the American Society for Radiation Oncology has positioned him to influence practice guidelines and educational standards in the field. His research has been supported through multi-institutional clinical trials and collaborations with major cancer centers across the United States. Dr. Kavanagh leads research efforts in the Rocky Mountain Gamma Knife Center and contributes to the University of Colorado Cancer Center's radiation oncology program. His work with 4DCT-ventilation imaging has established a clinical research program focused on functional avoidance radiation therapy, which aims to preserve lung function while effectively treating tumors.
Associate Professor Andre Kyme is an academic staff member in the School of Biomedical Engineering at The University of Sydney. His research focuses on developing enabling technologies for biomedical imaging, including motion compensation in MRI/PET, robotic platforms for image-guided therapy, and cross-disciplinary applications like plant salt uptake analysis using PET. He collaborates with institutions globally and advises students on projects like lameness detection in horses and AI-based motion correction. Research Interests: Kyme's work spans motion correction in medical imaging modalities, medical robotics integration with imaging systems, and innovative applications of imaging technologies in non-traditional fields. His team emphasizes leveraging advancements in computer vision, machine learning, and instrumentation to improve imaging performance and accessibility. Recent Projects: Current research includes MRI-compatible robotic platforms for therapy applications, AI-driven lameness detection in horses, and pediatric neuroimaging improvements. He leads the BREEZE initiative to enhance MRI accessibility for children with cerebral palsy through eye-gaze communication technology. Publications: His work spans 20+ years with over 50 peer-reviewed publications in journals like Physics in Medicine and Biology and IEEE Transactions. Key areas include PET/SPECT/CT motion correction algorithms, robotic systems for medical imaging, and novel imaging applications in plant science. Teaching: Kyme instructs core biomedical engineering courses including thesis supervision and capstone projects at both undergraduate and postgraduate levels. Labs/Teams: Active in the Brain and Mind Centre and Biomedical Imaging, Visualisation and Information Technologies groups at Sydney. Collaborates with industry partners like TeleMedVet and academic institutions including University of California Davis and Chinese University of Hong Kong.
Haoming Qiu, M.D. serves as an Associate Professor in the Department of Radiation Oncology at the University of Rochester School of Medicine and Dentistry. He practices clinically at both Wilmot Cancer Center in Rochester and Sands Cancer Center in Canandaigua, providing radiation oncology services for gastrointestinal, lung, and prostate cancers. Board-certified by the American Board of Radiology, Dr. Qiu specializes in advanced radiotherapy techniques including external beam radiation and radiopharmaceutical therapies. Education: MD, Johns Hopkins University (2011) Residency in Radiation Oncology, University of Rochester Medical Center (2013-2016) Residency in Radiation Oncology, Loyola University Medical Center (2012-2013) Internship in Internal Medicine, Sinai Hospital of Baltimore (2011-2012) Research Focus: Dr. Qiu's work centers on optimizing radiation therapy for gastrointestinal malignancies, prostate cancer, and neuroendocrine tumors. His investigations into theranostics explore novel applications of Lutathera for neuroendocrine tumors, Pluvicto for prostate cancer, and Therasphere for liver cancers. Current research emphasizes combining stereotactic body radiotherapy with immunotherapeutic agents to overcome treatment resistance in pancreatic and rectal cancers. Publication Trends: Recent publications (2023-2025) reveal a strategic shift toward adaptive radiotherapy techniques for pelvic malignancies and immunoradiotherapy combinations. His work demonstrates growing emphasis on modulating tumor immune microenvironments through radiation, particularly in pancreatic and rectal cancers. The integration of mRNA nanotechnology with SBRT represents a cutting-edge frontier in his research portfolio. Scientific Recognition: Roentgen Resident/Fellow Research Award (2015) Excellence in Medical Student Research (2011) Clinical Leadership: Dr. Qiu directs multiple clinical trials at the University of Rochester focusing on radiopharmaceutical applications and adaptive radiotherapy protocols. His patient-centered approach is reflected in consistently high patient satisfaction scores (4.9/5 stars) across communication, empathy, and treatment explanation metrics. Care Coordination: As part of the Wilmot Cancer Center and Sands Cancer Center teams, Dr. Qiu collaborates with multidisciplinary groups including medical oncologists, surgeons, and radiologists to deliver integrated cancer care through Accountable Health Partners network.
Andrew Godley, Ph.D., is the Associate Vice Chair of Clinical Physics Operations and Quality and an Associate Professor of Radiation Oncology at UT Southwestern Medical Center. He is part of the Department of Radiation Oncology’s Division of Medical Physics and Engineering. Dr. Godley holds a Texas Medical Physics License and is board-certified in therapeutic radiologic physics by the American Board of Radiology. Education: Received his Ph.D. in high-energy physics from the University of Sydney as part of the NOMAD experiment at CERN. Completed a postdoctoral fellowship at the University of South Carolina with the MINOS experiment at FermiLab. Transitioned to medical physics at the Medical College of Wisconsin. Research Interests: Focus on advanced radiation therapy techniques including brachytherapy, SBRT, Gamma Knife, MR-linac integration, and adaptive radiotherapy. His work emphasizes improving treatment accuracy, patient-specific quality assurance, and innovative approaches to personalized oncology care. Publications: Over 118 peer-reviewed articles, with recent work emphasizing adaptive radiotherapy strategies, MR-guided therapies, and computational tools for dose verification. Professional Contributions: Active in developing clinical protocols for radiation physics operations, including machine QA/commissioning and program development for new technologies like MR-linac systems.
Jingjing Zou is an Assistant Professor in Residence at the Herbert Wertheim School of Public Health & Human Longevity Science, University of California San Diego. Her research focuses on integrating statistical methodologies with medical imaging and public health challenges, particularly in cancer prevention, physical activity analysis, and radiomics. Education: PhD in Statistics, Columbia University MA in Statistics, Columbia University BS in Statistics, Peking University Research Interests: Dr. Zou's work emphasizes functional data analysis, accelerometer-based physical activity monitoring, and MRI techniques for cancer treatment evaluation. She develops statistical models to analyze longitudinal health data, with applications in cardiovascular disease prevention and oncology. Her studies often bridge clinical outcomes with advanced imaging biomarkers. Grants: NIH/NHLBI (Principal Investigator): Examining Longitudinal Changes in Accelerometer-Measured Physical Activity in Preventing Cardiovascular Disease (2024-2028) NIH R37CA249659 (Co-Investigator): Advanced diffusion MRI for cervical cancer treatment evaluation (2021-2026) NIH R01CA255780 (Co-Investigator): Whole-body radiomics for gynecologic cancers (2020-2024) Labs/Teams: Collaborates with interdisciplinary teams in radiology, oncology, and biostatistics, including co-authors like Loki Natarajan (UCSD) and Loren Mell (UCSD).
Knut Håkon Hole is an Associate Professor at the University of Oslo's Department of Radiology and Nuclear Medicine. His research focuses on diagnostic imaging applications in oncology, particularly in prostate and rectal cancers. He specializes in MRI, PET, and radiogenomics techniques to assess tumor biology, treatment response, and recurrence. Expertise: Prostate cancer imaging, neoadjuvant therapy response, tumor hypoxia, and imaging biomarkers Key affiliations: Oslo University Hospital (Rikshospitalet), Radium Hospital Research interests include: Developing MRI and PET protocols for cancer staging and recurrence detection Integrating imaging with genomic data (radiogenomics) Optimizing therapeutic approaches using imaging biomarkers Recent work highlights: Prostate cancer radiogenomics and hypoxia biomarkers (2024) MRI/PET comparisons for tumor localization (2021-2023) Neoadjuvant therapy response assessment in rectal and breast cancers (2020-2023) Publications span over 50 peer-reviewed articles with a focus on translational imaging research. Collaborates extensively with oncology and urology teams.
Prof Scott Crowe is a leading academic and clinical researcher in radiation oncology medical physics, affiliated with the Royal Brisbane and Women’s Hospital and the Hudson Institute of Medical Research (HBI) Cancer Care Services. His work bridges clinical practice and advanced research in radiotherapy technologies. Clinical Role: Clinical Lead for Cancer Care Services at HBI, overseeing radiation oncology medical physics. Education: Post-doctoral fellowship at Queensland University of Technology (QUT). Research Interests focus on: 3D Printing: Developing patient-specific phantoms and devices for radiotherapy applications (e.g., lung, vaginal, and oral molds). Dosimetry: Advancing measurement techniques (ionization chambers, Monte Carlo simulations) and addressing challenges like small field dose corrections, skin dose enhancement, and secondary cancer risk assessment. Adaptive Radiotherapy: Real-time motion adaptation systems, including Radixact Synchrony and TomoTherapy, to improve treatment accuracy. Quality Assurance: Statistical process control for beam energy variations, gamma evaluation methods, and machine performance checks. Publication Trends highlight his expertise in integrating 3D printing with dosimetry, optimizing adaptive radiotherapy workflows, and improving quality assurance protocols. His work spans Monte Carlo simulations , proton therapy , and image-guided radiotherapy . Supervision: Mentors higher degree research students in radiation oncology physics. Conferences: Regular presenter at international scientific meetings. Labs & Collaborations: Manages the radiation oncology medical physics research portfolio at Royal Brisbane and Women’s Hospital, collaborating with Hudson Institute on clinical translation projects.
.png)
